2019 Innovations Reports for Oncology

Oncology Services Banner

Dear Colleague:

We are proud to bring you our 2019 Report on Clinical and Scientific Innovations in Oncology. At NewYork-Presbyterian and our distinguished medical schools — Columbia University Vagelos College of Physicians and Surgeons and Weill Cornell Medicine — innovators in medicine and science are accelerating the discovery and development of novel diagnostic and therapeutic advances in cancer that are enabling us to achieve the best possible outcomes for patients.

Central to their endeavors are two major cancer centers: the National Cancer Institute-designated Herbert Irving Comprehensive Cancer Center at Columbia and the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine. Here, our cancer specialists collaborate on strategies for early detection and optimal diagnosis, develop groundbreaking therapies, and apply the latest technology and techniques to translate discoveries from the lab directly into the clinic.

In 2019, we were pleased to welcome two renowned gastrointestinal physician-scientists to lead cancer care and research programs at NewYork-Presbyterian. Anil K. Rustgi, MD, a global leader in GI cancers, has been appointed Director of the Herbert Irving Comprehensive Cancer Center and Chief of the Cancer Service at NewYork-Presbyterian/Columbia University Irving Medical Center. Manuel Hidalgo, MD, PhD, a pioneer in pancreatic cancer, has joined NewYork- Presbyterian/Weill Cornell Medical Center and Weill Cornell Medicine as Chief of the Division of Hematology and Medical Oncology. Dr. Rustgi and Dr. Hidalgo bring a wealth of experience and expertise that will help us advance our mission to provide the highest quality and most innovative cancer care for our patients.

In this report, we will share with you just some of the recent research developments in lung and genitourinary cancers, mantle cell lymphoma, myeloma, and glioblastoma. We believe that the eff orts of our clinicians and scientists will have a profound impact in ultimately changing the landscape of cancer care for years to come.